| 2.08 0.1 (5.05%) | 12-01 15:55 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.61 | 1-year : | 3.05 |
| Resists | First : | 2.24 | Second : | 2.61 |
| Pivot price | 1.79  |
|||
| Supports | First : | 1.69 | Second : | 1.36 |
| MAs | MA(5) : | 2.06 |
MA(20) : | 1.72 |
| MA(100) : | 2.32 |
MA(250) : | 2.8 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 71.7 |
D(3) : | 74.9 |
| RSI | RSI(14): 62.6 |
|||
| 52-week | High : | 4 | Low : | 1.36 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ AEZS ] has closed below upper band by 21.9%. Bollinger Bands are 104.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 2.06 - 2.08 | 2.08 - 2.09 |
| Low: | 1.93 - 1.95 | 1.95 - 1.96 |
| Close: | 1.96 - 1.98 | 1.98 - 2 |
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen brand name. Aeterna Zentaris Inc. has a license agreement with University Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and to develop human 3D intestinal tissue models to study infection biology; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd., Novo Nordisk Novo Nordisk Health Care AG, and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the United States and Canada, as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.
Fri, 24 Nov 2023
Is AEterna Zentaris Inc. (AEZS) a Stock to Watch After Gaining 19.88% This Week? - InvestorsObserver
Thu, 09 Nov 2023
North American Morning Briefing: Traders Await -2- - Morningstar
Thu, 09 Nov 2023
Aeterna Zentaris Reports Third Quarter 2023 Financial Results - Yahoo Finance
Wed, 11 Oct 2023
Aeterna Zentaris to Participate at the Virtual Investor Ask the CEO ... - GlobeNewswire
Thu, 13 Jul 2023
Aeterna Zentaris Outlines Progress on Development Pipeline ... - GlobeNewswire
Wed, 14 Jun 2023
Aeterna Zentaris Announces Results of Virtual 2023 Meeting of ... - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 4.85e+006 (%) |
| Held by Institutions | 0.4 (%) |
| Shares Short | 62 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.57e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -151 % |
| Return on Assets (ttm) | 666.6 % |
| Return on Equity (ttm) | -18.1 % |
| Qtrly Rev. Growth | 6.86e+006 % |
| Gross Profit (p.s.) | -48.93 |
| Sales Per Share | -30.27 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -4.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -15 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.07 |
| Price to Cash Flow | 0.78 |
| Dividend | 0 |
| Forward Dividend | 46750 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|